Movement Alert｜Illumina Rises 5.24% in Regular Trading, RBC Ups Target to $310 on Clinical Growth Outlook

Market Focus01:29

October 6, Illumina rose 5.24% in regular trading, trading at $287.345/share during this move. The surge follows RBC Capital Markets raising the stock's price target to $310 from $230 while maintaining Outperform rating.

RBC expects Illumina's clinical sequencing revenue to sustain mid-teens growth driven by oncology volume expansion and easing pricing pressures. Key catalysts include adoption surge in minimal residual disease testing, expanded approvals of tumor profiling, and coverage inclusion for colorectal cancer tests. BioInsight data solutions are projected to add 1-2 percentage points to fiscal 2027 growth while academic demand should bottom that year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment